BRIDGEWATER, NJ--(Marketwire - October 30, 2007) - Sapphire Therapeutics, Inc., a private biopharmaceutical company that develops new medicines acting on the ghrelin receptor for metabolic and oncologic diseases, has licensed a discovery-stage ghrelin antagonist program from Novo Nordisk. Ghrelin receptor antagonists are a new therapeutic target for the continuing unmet need for improved obesity treatments.
